DeepMed Research

Ascentage Pharma Group Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Interventions: Drug: HQP1351

First Posted Date: 2019-03-20

Last Posted Date: 2020-01-22

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 12

Registration Number: NCT03882281

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia - Accelerated Phase

Interventions: Drug: HQP1351

First Posted Date: 2019-03-20

Last Posted Date: 2023-04-03

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 23

Registration Number: NCT03883100

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guandong, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

and more 6 locations

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Interventions: Drug: HQP1351

First Posted Date: 2019-03-20

Last Posted Date: 2023-04-03

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 41

Registration Number: NCT03883087

Locations: 🇨🇳
Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

and more 7 locations

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Melanoma
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Uveal Melanoma
P53 Mutation
MDM2 Gene Mutation
Cutaneous Melanoma
Mucosal Melanoma
Malignant Peripheral Nerve Sheath Tumors (MPNST)

First Posted Date: 2018-08-02

Last Posted Date: 2024-07-19

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 230

Registration Number: NCT03611868

Locations: 🇺🇸
UCLA Hematology & Oncology Clinic, Los Angeles, California, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 18 locations

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Phase 1

Recruiting

Conditions: Gastrointestinal Stromal Tumor (GIST)
Solid Tumor, Adult

Interventions: Drug: HQP1351

First Posted Date: 2018-07-20

Last Posted Date: 2025-02-27

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 100

Registration Number: NCT03594422

Locations: 🇨🇳
Chinese PLA general hospital, Beijing, China, Beijing, China
🇨🇳
Guangdong general hospital, Guangzhou, Guangdong, China
🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

and more 3 locations

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: APG-1387 for Injection

First Posted Date: 2018-07-13

Last Posted Date: 2021-11-08

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 49

Registration Number: NCT03585322

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Early Phase 1

Recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: APG-2575

First Posted Date: 2018-05-25

Last Posted Date: 2024-08-19

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 90

Registration Number: NCT03537482

Locations: 🇺🇸
Duke Unviersity, Durham, North Carolina, United States
🇺🇸
MDACC, Houston, Texas, United States
🇦🇺
St. Vincent Hospital, Fitzroy, Victoria, Australia

and more 2 locations

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Phase 1

Terminated

Conditions: Small Cell Lung Cancer and Other Solid Tumors

Interventions: Drug: APG-1252

First Posted Date: 2018-01-02

Last Posted Date: 2021-08-27

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 24

Registration Number: NCT03387332

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumors or Hematologic Malignancies

Interventions: Drug: APG-1387 for Injection

First Posted Date: 2017-12-29

Last Posted Date: 2023-02-01

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 90

Registration Number: NCT03386526

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Phase 1

Completed

Conditions: Small Cell Lung Cancer
Solid Tumor

Interventions: Drug: APG-1252

First Posted Date: 2017-03-15

Last Posted Date: 2022-07-12

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 50

Registration Number: NCT03080311

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy